122P Casdozokitug (casdozo, SRF388), a first-in-class IL-27 targeting antibody, as monotherapy (monotx) or in combination with pembrolizumab (pembro) in treatment-refractory non-small cell lung cancer (NSCLC)
T.U. Marron, A. Naing, C. Mantia, N. Pennell, H.R. Kim, L. Villaruz, A.B. El-Khoueiry, D.E. Gerber, A. Qin, T-Y. Kim, M. Altan, L. Gandhi, L. J. Appleman, S. Yoon, J. Hill, V. Reichert, R. Masia, L. Harshman, A. Patnaik, D. Morgensztern
{"title":"122P Casdozokitug (casdozo, SRF388), a first-in-class IL-27 targeting antibody, as monotherapy (monotx) or in combination with pembrolizumab (pembro) in treatment-refractory non-small cell lung cancer (NSCLC)","authors":"T.U. Marron, A. Naing, C. Mantia, N. Pennell, H.R. Kim, L. Villaruz, A.B. El-Khoueiry, D.E. Gerber, A. Qin, T-Y. Kim, M. Altan, L. Gandhi, L. J. Appleman, S. Yoon, J. Hill, V. Reichert, R. Masia, L. Harshman, A. Patnaik, D. Morgensztern","doi":"10.1016/j.iotech.2023.100594","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":" 24","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-Oncology and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.iotech.2023.100594","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
